WO2009091826A3 - Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) - Google Patents

Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) Download PDF

Info

Publication number
WO2009091826A3
WO2009091826A3 PCT/US2009/030998 US2009030998W WO2009091826A3 WO 2009091826 A3 WO2009091826 A3 WO 2009091826A3 US 2009030998 W US2009030998 W US 2009030998W WO 2009091826 A3 WO2009091826 A3 WO 2009091826A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
compositions
methods related
car
specific chimeric
Prior art date
Application number
PCT/US2009/030998
Other languages
French (fr)
Other versions
WO2009091826A9 (en
WO2009091826A2 (en
Inventor
Laurence J.N. Cooper
Pallavi Manuri
Simon Olivares
Original Assignee
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Texas System filed Critical The Board Of Regents Of The University Of Texas System
Publication of WO2009091826A2 publication Critical patent/WO2009091826A2/en
Publication of WO2009091826A9 publication Critical patent/WO2009091826A9/en
Publication of WO2009091826A3 publication Critical patent/WO2009091826A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Embodiments of the invention include compositions and methods related to a human CD19-specific chimeric T cell receptor polypeptide comprising an intracellular signaling domain, a transmembrane domain and an extracellular domain, the extracellular domain comprising a human CD 19 binding region.
PCT/US2009/030998 2008-01-14 2009-01-14 Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) WO2009091826A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2099108P 2008-01-14 2008-01-14
US61/020,991 2008-01-14

Publications (3)

Publication Number Publication Date
WO2009091826A2 WO2009091826A2 (en) 2009-07-23
WO2009091826A9 WO2009091826A9 (en) 2009-09-24
WO2009091826A3 true WO2009091826A3 (en) 2009-11-19

Family

ID=40885876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/030998 WO2009091826A2 (en) 2008-01-14 2009-01-14 Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)

Country Status (1)

Country Link
WO (1) WO2009091826A2 (en)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
WO2008097926A2 (en) 2007-02-02 2008-08-14 Yale University Transient transfection with rna
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
DK2649086T3 (en) * 2010-12-09 2017-09-18 Univ Pennsylvania USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER
SG193023A1 (en) * 2011-02-11 2013-10-30 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
JP6082997B2 (en) 2011-04-01 2017-02-22 メモリアル スローン−ケタリング キャンサー センター T cell receptor-like antibody to WT1 peptide presented by HLA-A2
CN102735841B (en) * 2011-04-13 2014-11-05 苏州卫生职业技术学院 Method for detecting content of soluble CD28 in blood of patients suffering Graves disease
GB201108236D0 (en) * 2011-05-17 2011-06-29 Ucl Business Plc Method
US9193595B2 (en) 2011-06-21 2015-11-24 Drexel University Compositions comprising free-standing two-dimensional nanocrystals
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
EA201490636A1 (en) * 2011-09-16 2014-08-29 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания T-CELLS DESIGNED WITH THE HELP OF RNA FOR THE TREATMENT OF MALIGNOUS NON-FORMATIONS
WO2013126712A1 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
EP2828290B1 (en) 2012-03-23 2018-08-15 The United States of America, represented by the Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
CA2869562C (en) 2012-04-11 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
ES2719495T3 (en) 2012-05-07 2019-07-10 Dartmouth College Antibody directed against b7-h6, fusion proteins, and methods of use thereof
IN2014DN10991A (en) 2012-05-25 2015-09-25 Cellectis
CN103483452B (en) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 Dual signal independent chimeric antigen receptors and uses thereof
US20140120136A1 (en) * 2012-10-12 2014-05-01 The Babraham Institute Mir-155 enhancement of cd8+ t cell immunity
WO2014065961A1 (en) 2012-10-24 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
ES2776698T3 (en) * 2012-12-20 2020-07-31 Purdue Research Foundation T cells expressing a chimeric antigen receptor as cancer therapy
US20160015749A1 (en) * 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
CN105407902A (en) * 2013-03-05 2016-03-16 贝勒医学院 Oncolytic virus
UY35468A (en) * 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
US9790282B2 (en) * 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
PT2981607T (en) 2013-04-03 2020-11-20 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CN107460201A (en) * 2013-05-08 2017-12-12 科济生物医药（上海）有限公司 Encode the nucleic acid of the Chimeric antigen receptor albumen of GPC 3 and express the T lymphocytes of the Chimeric antigen receptor albumen of GPC 3
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
MX2015015662A (en) * 2013-05-13 2016-09-16 Cellectis Cd19 specific chimeric antigen receptor and uses thereof.
JP6463577B2 (en) 2013-05-14 2019-02-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Human application of modified chimeric antigen receptor (CAR) T cells
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
NZ719840A (en) * 2013-10-31 2023-01-27 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CN106414748B (en) * 2014-02-14 2021-05-28 得克萨斯州大学系统董事会 Chimeric antigen receptor and method of preparation
KR20160116018A (en) 2014-02-25 2016-10-06 아칠리온 파르마세우티칼스 인코포레이티드 Amide compounds for treatment of complement mediated disorders
ES2939760T3 (en) * 2014-03-15 2023-04-26 Novartis Ag Cancer treatment using a chimeric receptor for antigens
IL280215B (en) 2014-04-07 2022-07-01 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2015164759A2 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Mnd promoter chimeric antigen receptors
CA2951045A1 (en) 2014-06-02 2015-12-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting cd-19
CA2951044C (en) 2014-06-06 2023-10-03 Bluebird Bio, Inc. Improved t cell compositions
US20170226216A1 (en) 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
TWI751102B (en) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 Antibodies and chimeric antigen receptors specific for cd19
WO2016049109A2 (en) 2014-09-25 2016-03-31 Drexel University Physical forms of mxene materials exhibiting novel electrical and optical characteristics
CN106973568B (en) 2014-10-08 2021-07-23 诺华股份有限公司 Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
EP3536707A1 (en) * 2014-11-05 2019-09-11 Board of Regents, The University of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2016077526A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN107207598B (en) 2014-12-12 2020-12-08 蓝鸟生物公司 BCMA chimeric antigen receptors
ES2842212T3 (en) 2015-01-26 2021-07-13 Cellectis Anti-CLL1 Specific Single Chain Chimeric Antigen Receptors (scCAR) for Cancer Immunotherapy
JP6800859B2 (en) 2015-01-26 2020-12-16 フェイト セラピューティクス，インコーポレイテッド Methods and Compositions for Inducing Hematopoietic Cell Differentiation
US10538431B2 (en) 2015-03-04 2020-01-21 Drexel University Nanolaminated 2-2-1 MAX-phase compositions
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
WO2017011044A2 (en) 2015-04-20 2017-01-19 Drexel University Two-dimensional, ordered, double transition metals carbides having a nominal unit cell composition m'2m"nxn+1
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
CA2990177A1 (en) 2015-06-25 2016-12-29 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
WO2017222593A1 (en) 2016-06-24 2017-12-28 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
CN108174604B (en) 2015-08-07 2023-06-23 西雅图儿童医院（Dba西雅图儿童研究所） Bispecific CAR T cells for solid tumor targeting
WO2017035362A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR105808A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
AR105809A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
CN116334205A (en) 2015-09-03 2023-06-27 诺华股份有限公司 Biomarkers for predicting cytokine release syndrome
CN106554414B (en) * 2015-09-18 2019-04-23 上海科济制药有限公司 Anti- CD19 human antibody and the immune effector cell for targeting CD19
AU2016348342B2 (en) 2015-11-04 2023-07-06 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
PT3371314T (en) 2015-11-04 2023-08-31 Fate Therapeutics Inc Genomic engineering of pluripotent cells
CN116217729A (en) 2015-11-12 2023-06-06 思进公司 Glycan interaction compounds and methods of use
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
JP6676182B2 (en) 2016-02-23 2020-04-08 バイオラインアールエックス・リミテッドＢｉｏＬｉｎｅＲｘ Ｌｔｄ． How to treat acute myeloid leukemia
CN107815465B (en) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized gene modified animal model
US11279948B2 (en) 2016-08-31 2022-03-22 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric OX40
TW202340473A (en) 2016-10-07 2023-10-16 瑞士商諾華公司 Treatment of cancer using chimeric antigen receptors
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
CN110291200B (en) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） Agent ligand induction of transgene expression in mammalian cells
CN108424928B (en) * 2016-12-30 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized gene modified animal model
EP3346001A1 (en) * 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288A (en) 2017-02-28 2019-12-17 恩多塞特公司 Compositions and methods for CAR T cell therapy
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
ES2933513T3 (en) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Macrocyclic compounds for the treatment of medical disorders
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
JP2020510671A (en) 2017-03-03 2020-04-09 シアトル ジェネティックス， インコーポレイテッド Glycan interacting compounds and methods of use
WO2018170506A1 (en) * 2017-03-17 2018-09-20 University Of Tennessee Research Foundation Methods of using cytotoxic t cells for treatment of autoimmune diseases
CN107058232B (en) * 2017-04-12 2018-03-30 上海优卡迪生物医药科技有限公司 Cholesterol turns repressed CAR T cells of lipase SOAT1 and its preparation method and application
US20220233588A1 (en) 2017-06-30 2022-07-28 Cellectis Cellular immunotherapy for repetitive administration
WO2019027650A1 (en) 2017-08-01 2019-02-07 Drexel University Mxene sorbent for removal of small molecules from dialysate
EP4279086A3 (en) * 2017-09-15 2024-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19 immunotherapy
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
BR112020007710A2 (en) * 2017-10-25 2020-10-20 Novartis Ag methods to produce cells that express chimeric antigen receptor
BR112020014913A2 (en) 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) METHODS FOR USE OF T CAR CELLS
WO2019154313A1 (en) 2018-02-11 2019-08-15 江苏恒瑞医药股份有限公司 Isolated chimeric antigen receptor, modified t cell comprising same and use thereof
AU2019234926A1 (en) 2018-03-15 2020-10-08 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2019217253A1 (en) * 2018-05-07 2019-11-14 Children's Hospital Medical Center Chimeric polypeptides, nucleic acid molecules, cells, and related methods
US11470424B2 (en) 2018-06-06 2022-10-11 Drexel University MXene-based voice coils and active acoustic devices
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
AU2019336238A1 (en) 2018-09-06 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of Complement factor D inhibitors
KR20210093855A (en) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 Conformational forms of complement factor D inhibitors
MX2021006968A (en) 2018-12-12 2021-10-13 Kite Pharma Inc Chimeric antigen receptors and car-t cells and methods of use.
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN112210007B (en) * 2019-07-11 2022-07-12 华夏英泰（北京）生物技术有限公司 CD19 antigen high-affinity antibody and chimeric antigen receptor comprising CD19 single-chain antibody region thereof
US20230073449A1 (en) 2020-01-23 2023-03-09 The Children's Medical Center Corporation Stroma-free t cell differentiation from human pluripotent stem cells
EP4114449A2 (en) 2020-03-05 2023-01-11 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126363A1 (en) * 2000-11-07 2004-07-01 Jensen Michael C. Cd19-specific redirected immune cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126363A1 (en) * 2000-11-07 2004-07-01 Jensen Michael C. Cd19-specific redirected immune cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLAUDIA M. KOWOLIK ET AL.: "CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.", CANCER RES., vol. 66, no. 22, 2006, pages 10995 - 11004 *
LAURENCE J. N. COOPER ET AL.: "Enhanced antilymphoma efficacy of CD19-redirected influenza MPl-specific CTLs by cotransfer of T cells modified to present influenza MP1.", BLOOD., vol. 105, no. 4, 2005, pages 1622 - 1631 *
LAURENCE J. N. COOPER ET AL.: "T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.", BLOOD, vol. 101, no. 4, 2003, pages 1637 - 1644 *
RENIER J. BRENTJENS ET AL.: "Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.", CLIN. CANCER RES., vol. 13, no. 18, 2007, pages 5426 - 5435 *
TINA MULLER ET AL.: "Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity ofNK cells and overcomes NK-resistance of lymphoma and leukemia cells.", CANCER IMMUNOL. IMMUNOTHER., vol. 57, 24 August 2007 (2007-08-24), pages 411 - 423 *
TONTANAI NUMBENJAPON ET AL.: "Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.", EXPERIMENTAL HEMATOLOGY., vol. 35, 2007, pages 1083 - 1090 *

Also Published As

Publication number Publication date
WO2009091826A9 (en) 2009-09-24
WO2009091826A2 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
WO2009091826A3 (en) Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2017172981A3 (en) Chimeric antigen receptors targeting cancer
MY159679A (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
MX2021012720A (en) Costimulatory chimeric antigen receptor t cells targeting il13rî±2.
WO2010003101A3 (en) Il6 immunotherapeutics
WO2010016766A3 (en) Antibodies recognizing endogenous human lgr5 and/or lgr6
WO2008045437A3 (en) Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
WO2010037041A3 (en) Frizzled-binding agents and uses thereof
WO2017079694A3 (en) Chimeric antigen receptors targeting her2
WO2006000830A3 (en) Cells expressing a modified t cell receptor
WO2014074532A3 (en) Compositions and methods for modulating cell signaling
MY155621A (en) Axl antibodies
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
NZ592420A (en) Cd86 antagonist multi-target binding proteins
WO2008059252A3 (en) Methods and composition fro t cell receptors which recognize 5t4 antigen
WO2011119979A3 (en) Antibodies to muc16 and methods of use thereof
MX2022006962A (en) Lilrb1-based chimeric antigen receptor.
WO2017066481A8 (en) Chimeric antigen receptors containing a chlorotoxin domain
WO2007076070A3 (en) Modulators of muscarinic receptors
NZ618129A (en) Compositions of humanized notch fusion proteins and methods of treatment
WO2011123785A3 (en) Frizzled-binding agents and uses thereof
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
WO2008093688A1 (en) CHIMERIC Fcγ RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR
IL194752A0 (en) Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09702675

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09702675

Country of ref document: EP

Kind code of ref document: A2